Geode Capital Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,785,586
| Closed | -$84.8M | – | 4474 |
|
|
2025
Q3 | $84.8M | Buy |
1,785,586
+63,181
| +4% | +$3.06M | 0.01% | 1178 |
|
|
2025
Q2 | $91.9M | Sell |
1,722,405
-26,789
| -2% | -$1.22M | 0.01% | 1076 |
|
|
2025
Q1 | $70.8M | Buy |
1,749,194
+189,563
| +12% | +$8.03M | 0.01% | 1170 |
|
|
2024
Q4 | $43.4M | Sell |
1,559,631
-11,381
| -0.7% | -$345K | ﹤0.01% | 1512 |
|
|
2024
Q3 | $45.1M | Sell |
1,571,012
-48,027
| -3% | -$1.25M | ﹤0.01% | 1488 |
|
|
2024
Q2 | $38M | Buy |
1,619,039
+199,732
| +14% | +$4.27M | ﹤0.01% | 1540 |
|
|
2024
Q1 | $35.9M | Buy |
1,419,307
+253,062
| +22% | +$6.08M | ﹤0.01% | 1578 |
|
|
2023
Q4 | $27.2M | Buy |
1,166,245
+62,939
| +6% | +$1.24M | ﹤0.01% | 1726 |
|
|
2023
Q3 | $55.8M | Buy |
1,103,306
+278,599
| +34% | +$13M | 0.01% | 1157 |
|
|
2023
Q2 | $38.5M | Buy |
824,707
+158,780
| +24% | +$7.28M | ﹤0.01% | 1422 |
|
|
2023
Q1 | $25.5M | Buy |
665,927
+32,547
| +5% | +$1.45M | ﹤0.01% | 1641 |
|
|
2022
Q4 | $34.7M | Buy |
633,380
+110,091
| +21% | +$4.72M | ﹤0.01% | 1397 |
|
|
2022
Q3 | $17.8M | Buy |
523,289
+55,304
| +12% | +$846K | ﹤0.01% | 1818 |
|
|
2022
Q2 | $4.42M | Buy |
467,985
+24,512
| +6% | +$256K | ﹤0.01% | 2767 |
|
|
2022
Q1 | $6.29M | Buy |
443,473
+26,792
| +6% | +$469K | ﹤0.01% | 2660 |
|
|
2021
Q4 | $8.81M | Buy |
416,681
+38,988
| +10% | +$865K | ﹤0.01% | 2538 |
|
|
2021
Q3 | $8.44M | Buy |
377,693
+15,115
| +4% | +$342K | ﹤0.01% | 2586 |
|
|
2021
Q2 | $8.99M | Buy |
362,578
+98,095
| +37% | +$2.76M | ﹤0.01% | 2529 |
|
|
2021
Q1 | $7.67M | Buy |
264,483
+22,821
| +9% | +$691K | ﹤0.01% | 2544 |
|
|
2020
Q4 | $6.23M | Buy |
241,662
+7,792
| +3% | +$217K | ﹤0.01% | 2480 |
|
|
2020
Q3 | $7.2M | Buy |
233,870
+93,903
| +67% | +$3.28M | ﹤0.01% | 2169 |
|
|
2020
Q2 | $3.49M | Buy |
139,967
+26,060
| +23% | +$596K | ﹤0.01% | 2527 |
|
|
2020
Q1 | $2.41M | Buy |
113,907
+34,663
| +44% | +$743K | ﹤0.01% | 2577 |
|
|
2019
Q4 | $1.76M | Buy |
79,244
+4,713
| +6% | +$97.5K | ﹤0.01% | 3068 |
|
|
2019
Q3 | $1.7M | Buy |
+74,531
| New | +$1.73M | ﹤0.01% | 3028 |
|
Other funds holding AKRO
Geode Capital Management's AKRO Position: Q4 2025 in Review
Geode Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,785,586 shares — an estimated $84.8M sold.
Geode Capital Management first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $91.9M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Geode Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Geode Capital Management sold 1,785,586 Akero Therapeutics shares in Q4 2025, an estimated $84.8M.
- Geode Capital Management first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Geode Capital Management's Akero Therapeutics position peaked at $91.9M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.